Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 27, 2018
Event: Regulation FD Disclosure (Item 7.01) and Financial Statements/Exhibits (Item 9.01).
This filing serves to furnish an investor presentation (Exhibit 99.1) dated November 2018, intended for use in meetings with investors or analysts. The information is furnished pursuant to Item 7.01 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a cover for an attached presentation rather than a standalone financial report containing audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are detailed within the text of this Form 8-K. The filing references an external presentation for detailed information.
Guidance, Outlook, and Risks
Management Commentary: The company is providing an investor presentation for use in subsequent meetings. The text explicitly states that the information is subject to modification.
Legal Disclaimer: The content is not incorporated by reference into other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference.
Risks: No specific risks or contingencies are enumerated in the body of this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (TherapeuticsMD, Inc. presentation dated November 2018) for actual financial data and strategic outlook.
- Verify if the presentation has been modified since the filing date of November 27, 2018.
- Check subsequent filings to see if the information in this presentation was incorporated by reference.
- Confirm the identity of the authorized signatory: Daniel A. Cartwright, Chief Financial Officer.